TERTp contains binding sites STAT3 and is overexpressed in prostate, breast, head, neck, and hematologic cancers, which implicates STAT3 as an important anticancer target (105). This evidence concerns the gene STAT3 and hematopoietic and lymphoid cell neoplasm.